Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Provided By GlobeNewswire
Last update: Sep 25, 2024
- Patients are preselected for CDKN2A and/or CDKN2B abnormalities -
- Safety and efficacy data to be reported at an upcoming oncology medical conference -
Read more at globenewswire.comCYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (2/21/2025, 8:11:33 PM)
7.39
-0.55 (-6.93%)
0.34
-0.01 (-1.73%)
Find more stocks in the Stock Screener
